Deep Vein Thrombosis
Conditions
Brief summary
The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (RFA). People who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat their condition. Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies require the puncture of the leg veins . Previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg. It is not known whether giving blood thinners (anticoagulants) after the procedure will decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs
Interventions
DRUGClexane
Sponsors
Sanofi
National Heart Foundation, Australia
Melbourne Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on patient history or ECG evidence.
Exclusion criteria
* Patients with a past history of DVT or PE. * Patients with a history of clotting disorders * Patients with active malignancies * Patients requiring full heparinisation during and after the procedure. * Chronic atrial flutter and atrial fibrillation ablation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of deep vein thrombosis | 1 year |
Countries
Australia
Outcome results
None listed